J&J's Risperdal "Not Approvable" In Alzheimer's Psychosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The company issues its second announcement in a week that Risperdal has been deemed not approvable for a supplemental indication; FDA also issued a not approvable letter for risperidone for the treatment of autism.
You may also be interested in...
Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.
Forest’s Namenda Gets “Not Approvable” Letter For Mild Alzheimer’s Indication
The firm blames supplementary studies – which found numerical improvement for the memantine cohort but failed to meet statistical significance – for the denial.
J&J's Risperdal "Not Approvable" For Autism
FDA issues a "not approvable" letter for risperidone, despite the agency's mid-2004 determination that the antipsychotic was "approvable" for autism. J&J is considering the "appropriate next steps" for the indication.